Mepolizumab use: post-approval academic practice experience

Severe asthma of the eosinophilic subtype is associated with significant morbidity and mortality and health-care costs due to recurrent asthma exacerbations and need for treatment with oral corticosteroids 1,2. Thus, steroid-sparing medications for eosinophilic asthma have been sought to improve outcomes in these patients.

https://ift.tt/2GNGS2l